TAFI gene polymorphisms in patients with cerebral venous thrombosis

Acta Neurologica Belgica

Volumn 113, Issue 3, 2013, Pages 291-297

  Tokgoz, Serhat ^a   Zamani, Ayse Gul ^a   Durakbasi Dursun, Hatice Gul ^a   Yılmaz, Osman ^a   Ilhan, Nurhan ^a   Demirel, Sennur ^a   Tavli, Mithat ^a   Sinan, Alper ^b  

^a NECMETTIN ERBAKAN UNIVERSITY   (Turkey)

^b SINOP UNIVERSITY   (Turkey)

Author keywords

1040C>T; 438G>A; 505A>G; Cerebral venous thrombosis; Sinus thrombosis; TAFI

Indexed keywords

THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADULT; ALLELE; ARTICLE; CASE CONTROL STUDY; CEREBRAL SINUS THROMBOSIS; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITION FACTOR 1 GENE;

ADULT; CASE-CONTROL STUDIES; CEREBRAL VEINS; CHI-SQUARE DISTRIBUTION; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENOTYPE; HISTONE ACETYLTRANSFERASES; HUMANS; INTRACRANIAL THROMBOSIS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; TATA-BINDING PROTEIN ASSOCIATED FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TRANSCRIPTION FACTOR TFIID; YOUNG ADULT;

EID: 84883428584     PISSN: 03009009     EISSN: 22402993     Source Type: Journal    
DOI: 10.1007/s13760-012-0170-6     Document Type: Article

References (32)

1. Bousser MG (2000) Cerebral venous thrombosis: diagnosis and management. J Neurol 247: 252-258.
2. De Keyze K, Paemeleire K, De Clerck M, Peeters D, De Reuck JL (2004) Diabetic ketoacidosis presenting as a cerebral venous sinus thrombosis. Acta Neurol Belg 104: 117-120.
3. Gökçil Z, Odabasi Z, Vural O, Yardim M (1998) Cerebral venous thrombosis in pregnancy: the role of protein S deficiency. Acta Neurol Belg 98: 36-38.
4. Hajjar KA, Francis CW (2006) Fibrinolysis and thrombolysis. In: Lichtman MA, Beutler E, Kipps TJ et al (eds) Williams Hematology. McGraw-Hill, New York, pp 2089-21152.
5. Boffa MB, Wang W, Bajzar L, Nesheim ME (1998) Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties. J Biol Chem 273: 2127-2135.
6. Leurs J, Hendriks D (2005) Carboxypeptidase U (TAFla): a metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease. Thromb Haemost 94: 471-487.
7. Eaton DL, Malloy BE, Tsai SP, Henzer W, Drayna D (1991) Isolation, molecular- cloning, and partial characterization of a novel carboxypeptidase-B from human plasma. J Biol Chem 266: 21833-21838.
8. Bajzar L, Manuel R, Nesheim ME (1995) Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 270: 14477-14484.
9. Meltzer ME, Doggen CJM, de Groot PhG, Meijers JCM, Rosendaal FR, Lisman T (2009) Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men. Haematologica 94: 811-818.
10. Santamaria A, Oliver A, Borrel M, Mateo J, Belvis R, Marti-Fabregas J, Ortin R, Tirado I, Souto JC, Fontcuberta J (2003) Risk of i{dotless}schemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels. Stroke 34: 2387-2391.
11. Montaner J, Ribó M, Monasterio J, Molina Carlos A, Alvarez-Sabín José (2003) Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke 34: 1038-1040.
12. Leebeek FWG, van Goor MPJ, Guimaraes AHC, Brouwers G-J, de Maat MPM, Dippel DWJ, Rijken DC (2005) High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J Thromb Haemost 3: 2211-2218.
13. Eichinger S, Schonauer V, Weltermann A, Minar E, Bialonczyk C, Hirschl M, Schneider B, Quehenberger P, Kyrle PA (2004) Thrombin activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 103: 3773-3776.
14. van Tilburg NH, Rosendaal FR, Bertina RM (2000) Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 95: 2855-2859.
15. Libourel EJ, Bank I, Meinardi JR, Baljé -Volkers CP, Hamulyak K, Middeldorp S, Koopman MM, van Pampus EC, Prins MH, Büller HR, van der Meer J (2002) Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism. Haematologica 87: 1068-1073.
16. Franco RF, Fagundes MG, Meijers JCM, Reitsma PH, Lourenço D, Morelli V, Maffei FH, Ferrari IC, Piccinato CE, Silva WA Jr, Zago MA (2001) Identification of polymorphisms in the 5′-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica 86: 510-517.
17. Ladenvall C, Gils A, Jood K, Blomstrand C, Paul J, Declerck PJ, Jern C (2007) Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation. Arterioscler Thromb Vasc Biol 27: 955-962.
18. Wang X, Smith PL, Hsu MY, Tamasi JA, Bird E, Schumacher WA (2007) Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis. J Thromb Thrombolysis 23: 41-49.
19. Meltzer ME, Bol L, Rosendaal FR, Lisman T, Cannegieter SC (2010) Hypofibrinolysis as a risk factor for recurrent venous thrombosis; results of the LETS follow-up study. J Thromb Haemost 8: 605-607.
20. Kraft P, Schwarz T, Meijers JCM, Stoll G, Kleinschnitz C (2010) Thrombin-activatable fibrinolysis inhibitor (tafi) deficient mice are susceptible to intracerebral thrombosis and ischemic stroke. PLoS ONE 5: e11658.
21. Morange PE, Tregouet DA, Frere C, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Cambien F, Tiret L, Juhan-Vague I, Prime Study Group (2005) TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study. J Thromb Haemost 3: 1503-1510.
22. Henry M, Aubert H, Morange P, Nanni I, Alessi M, Tiret L, Juhan-Vague I (2001) Identification of polymorphisms in the promoter and the 39 region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 97: 2053-2058.
23. Brouwers GJ, Leebeek FW, Tanck MW, Wouter Jukema J, Kluft C, de Maat MP (2003) Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris. Thromb Haemost 90: 92-100.
24. Juhan-Vague I, Morange PE, HIFMECH Study Group et al (2002) Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol 22: 867-873.
25. Martini CH, Brandts A, de Bruijne EL, van Hylckama Vlieg A, Leebeek FW, Lisman T, Rosendaal FR (2006) The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis. Br J Haematol 134: 92-94.
26. Akatsu H, Yamagata H, Chen Y, Miki T, Kamino K, Takeda M, Campbell W, Kondo I, Kosaka K, Yamamoto T, Okada H (2004) TAFI polymorphisms at amino acids 147 and 325 are not risk factors for cerebral infarction. Br J Haematol 127: 440-447.
27. Lichy C, Dong-Si T, Reuner K, Genius J, Rickmann H, Hampe T, Dolan T, Stoll F, Grau A (2006) Risk of cerebral venous thrombosis and novel gene polymorphisms of the coagulation and fibrinolytic systems. J Neurol 253: 316-320.
28. de Bruijne EL, Gils A, Guimarães AH, Dippel DW, Deckers JW, van den Meiracker AH, Poldermans D, Rijken DC, Declerck PJ, de Maat MP, Leebeek FW (2009) The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study. J Thromb Haemost 7: 919-927.
29. Tassies D, Roque M, Monteagudo J, Martorell T, Sionis A, Arzomendi D, Heras M, Reverter JC (2009) Thrombin-activatable fibrinolysis inhibitor genetic polymorphisms as markes of the type of acute coronary syndrome. Thromb Res 124: 614-618.
30. Kozian DH, Lorenz M, März W, Cousin E, Mace S, Deleuze JF (2010) Association between the Thr325Ile polymorphism of the thrombin-activatable fibrinolysis inhibitor and stroke in the Ludwigshafen Risk and Cardiovascular Health Study. Thromb Haemost 103: 976-983.
31. Heylen E, Miljic P, Willemse J, Djordjevic V, Radojkovic D, Colovic M, Elezovic I, Hendriks D (2009) Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia. Thromb Res 124: 427-432.
32. Verdu J, Marco P, Benlloch S, Lucas J (2008) Association between the Thr325Ile and Ala147Thr Polymorphisms of the TAFI Gene and the Risk of Venous Thromboembolic Disease. Clin Appl Thromb Hemost 14: 494.